The expression of all 8 CCT members was increased in cholangiocarcinoma, colon adenocarcinoma, esophageal carcinoma, head and neck squamous cell carcinoma, liver hepatocellular carcinoma, LUAD, LUSC, prostate adenocarcinoma, rectum adenocarcinoma, and stomach adenocarcinoma, except for CCT6B. Here, FLVCR2 is linked to gastric adenocarcinoma.